Immunogenetic aspects of neuropediatric disorders
the role of the human histocompatibility antigens
DOI:
https://doi.org/10.34024/rnc.2007.v15.8734Keywords:
HLA antigens, Major histocompatibility complex, Child, AdolescentAbstract
Objective: Update the human histocompatibility antigens (HLA) associations with neuropediatric disorders and describe its possible pathogenic mechanisms. Data research: Bibliographic search was made using the MEDLINE and LILACS data base between 1990 and 2005. The articles approaching the association of HLA and neurological diseases were selected. Additional references were selected by manual search from the previous selected articles. Results: This paper is organized in topics that describe and discuss the possible mechanisms of how structure and function of HLA molecules influence the development of neurological diseases in children. Conclusion: The association of HLA system with some childhood neurological diseases is well established such as in myasthenia gravis. However, more studies are necessary to confirm preliminary data suggestive of this association with other neurological disorders. The establishment of stronger associations may allow the use of the HLA system to evaluate the risk that a person who carries an allele or haplotype have to develop a specific disease and contribute to a better understanding of its pathogenic mechanisms.
Metrics
References
Klein J, Sato A. The HLA System. First of two parts. N Engl J Med 2000; 343(10): 702-709.
Alves C, Souza T, Veiga S, Alves CA, Toralles MB, Lemaire D. Importância do sistema de histocompatibilidade humano (HLA) em Pediatria. Pediatria (São Paulo) 2005; 27(4): 274-286.
Donadi EA. Aspectos moleculares do complexo principal de histocompatibilidade: como entender a associação entre o sistema HLA e as doenças reumáticas. Rev Bras Reumatol 2001; 41(4): 225-235.
Probst CM, Bompeixe EP. HLA Polymorphism and evaluation of European, African, and Amerindians contribution to the white and mulatto population from Paraná, Brazil. Hum Biol 2000; 72(4): 597-617.
Castro-Cago M. Neurología pediátrica y genética: introducción. Rev Neurol 2002; 35(2): 145-148.
Almeida SM. O sistema nervoso central é um sítio imunologicamente privilegiado? Rev Bras Neurol 1999;35(4): 81-86.
Bradl M, Hohfeld R. Molecular pathogenesis of neuroinflamation. J Neurol Neurosurg Psychiatr 2003; 74: 1364–1370
Collawn JF, Benvenistre EN. Regulation of MHC class II expression in the central nervous system. For Immunol 1999; 893-902
Geleijns K, Schreuder GM, Jacobs BC, Sintnicolaas K, van Koningsveld R, Meulstee J, et al. HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome. Neurology 2005; 64(1): 44-49.
Li H, Yuan J, Hao H, Yan Z, Wang S. HLA alleles in patients with Guillain-Barré syndrome. Chin Med J (Engl) 2000; 113(5): 429-432.
Ma JJ, Nishimura M, Mine H, Kuroki S, Nukina M, Ohta M, et al. HLA and T-cell receptor gene polymorphisms in Guillain-Barre syndrome. Neurology 1998; 51(2):379-384.
Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004; 3(2): 104-110.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343(13): 938-952.
Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, Akesson E, et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatr 2002; 72(2): 184-187.
Dyment DA, Herrera BM, Cader MZ, Willer CJ, Lincoln MR, Sadovnick AD, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet. 2005; 14(14): 2019-2026.
Caballero A, Alves-Leon S, Papais-Alvarenga R, Fernandez O, Navarro G, Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians. Tissue Antigens 1999; 54(5): 524-526.
Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar M, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005; 37(10): 1108-1112.
Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357: 2122–2128.
Fernández-Mestre MT, Vargas V, Montagnani S, Cotúa M, Ogando V, Layrisse Z. HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis. Hum Immunol 2004; 65, 54–59.
Garcıa-Ramos G, Téllez-Zenteno JF, Zapata-Zúñiga M, Yamamoto-Furusho JK, Ruiz-Morales JA, Villarreal-Garza C, et al. HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis. Euro J Neurol 2003; 10: 707–710.
Shinomiya N, Nomura Y, Segawa M. A variant of childhood-onset myasthenia gravis: HLA typing and clinical characteristics in Japan. Clin Immunol 2004; 110: 154– 158.
Donadi EA, Smith AG, Louzada-Junior P, Voltarelli JC, Nepom GT. HLA class I and class II profiles of patients presenting with Sydenham’s chorea. J Neurol 2000; 247(2):122-128.
Stanevicha V, Eglite J, Sochnevs A, Gardovska D, Zavadska D, Shantere R. HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia. Arthritis Res Ther 2003; 5(6):340-346.
Biggar RJ, Ng J, Kim N, Hisada M, Li HC, Cranston B, et al. Human leukocyt antigen concordance and the transmission risk via breast-feeding of human T cell lymphotropic virus type I. J Infect Dis 2006; 193(2): 277-282.
Manns A, Hanchard B, Morgan OS, Wilks R, Cranston B, Nam JM, et al. Human leukocyte antigen class II alleles associated with human T-cell lymphotropic vírus Type I infection and adult T-cell leukemia/lymphoma in a Black population. J Natl Cancer Inst 1998; 90(8): 617-621.
Jeffery KJ, Usuku K, Matsumoto W, Matsumoto W, Taylor GP, Procter J, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 1999; 96(7): 3848-3853.
Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000; 165: 7278-7284.
Suzuki Y. Host resistance in the brain against Toxoplasma gondii. J Infect Dis 2002;185(Suppl 1):S58–S65
Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363(9425): 1965-1976.
Mack DG, Johnson JJ, Roberts F, et al. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol 1999; 29:1351–1358.
Del Brutto OH, Granados G, Talamas O, Sotelo J, Gorodezky C. Genetic pattern of the HLA system: HLA A, B, C, DR, and DQ antigens in Mexican patients with parenchymal brain cysticercosis. Hum Biol 1991; 63(1):85-93.
Bompeixe EP, Costa SMCM, Arruda WO, Petzl-Erler ML. Lack of association between parenchymal neurocysticercosis and HLA Class I and Class II antigens. Genet. Mol Biol 1999; 22(1): 7-11.
Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002; 168(9):4772-4780.
Maier S, Geraghty DE, Weiss EH. Expression and regulation of HLA-G in human glioma cell lines. Transplant Proc 1999; 31(4): 1849-1853.
Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, et al. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 2005; 85(3): 328-341.
Machulla HK, Steinborn F, Schaaf A, Heidecke V, Rainov NG. Brain glioma and human leukocyte antigens (HLA): Is there an association? J Neurooncol 2001; 52(3): 253-261.
Tang J, Shao W, Dorak MT, Li Y, Miike R, Lobashevsky E, et al. Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev 2005; 14(8): 2040-2044.
Corrias MV, Occhino M, Croce M, De Ambrosis A, Pistillo MP, Bocca P, et al. Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens 2001; 57(2): 110-117.
Raffaghello L, Prigione I, Airoldi I, et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett 2005; 228(1-2): 155-61.
Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, et al. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci 2004; 1028: 69-80.
Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, et al. Expression of MHC class I, MHC class II, and cancer germ line antigens in neuroblastoma. Cancer Immunol Immunother 2005; 54(4): 400-406.
Renganathan R, Delanty N. Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J 2003;79(928):78-80.
Greenberg DA, Durner M, Shinnar S, Resor S, Rosenbaum D, Klotz I, et al. Association of HLA class II alleles in patients with juvenile myoclonic epilepsy compared with patients with other forms of adolescent-onset generalized epilepsy. Neurology 1996; 47(3):750-755.
Le Hellard S, Neidhart E, Thomas P, Feingold J, Malafosse A, Tafti M. Lack of association between juvenile myoclonic epilepsy and HLA-DR13. Epilepsia 1999; 40(1): 117-119.
Greenberg DA, Durner M, Keddache M, Shinnar S, Resor SR, Moshe SL, et al. Reproducibility and complications in gene searches: linkage on chromosome 6, heterogeneity, association, and maternal inheritance in juvenile myoclonic epilepsy. Am J Hum Genet 2000; 66(2):508-516.
